Russia is preparing for a new wave of drug prices growth this year due to a new bill, designed by the national Parliament aimed at tightening a control for the activities of domestic pharmacies, The Pharma Letter’s local correspondent reports.
The new bill proposes to limit the so-called marketing bonuses of pharmacies, which may force them to increase prices by up to 20%. The clarification to the bill says that marketing campaigns distract pharmacists from work and force them to propose unnecessary drugs for customers.
It is planned that the growth of prices will not affect drugs from the list of vital, but will apply to the majority of other drugs available in the Russian market and will probably lead to the decline of their sales already in the short term.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze